5.2 Differentials in Genitourinary and Renal Conditions

Differentials in Genitourinary and Renal Conditions

Evaluating genitourinary and renal presentations in primary care requires the Family Nurse Practitioner (FNP) to distinguish between infectious, structural, and systemic chronic processes. Applying established clinical guidelines from the Infectious Diseases Society of America (IDSA), the American Urological Association (AUA), and Kidney Disease: Improving Global Outcomes (KDIGO) is essential for correct diagnosis and safe, evidence-based prescribing.

Urinary Tract Infections (UTIs)

Urinary Tract Infections are classified as uncomplicated (occurring in healthy, non-pregnant adult females) or complicated (occurring in males, pregnant females, patients with diabetes, immunosuppression, indwelling catheters, or anatomical abnormalities).

• Pathophysiology: Escherichia coli is the causative pathogen in 80–85% of cases. Other pathogens include Staphylococcus saprophyticus (common in young, sexually active females), Proteus mirabilis (associated with struvite stones), and Klebsiella pneumoniae.
• Clinical Presentation: Classic symptoms of cystitis include dysuria, frequency, urgency, suprapubic pain, and gross or microscopic hematuria. Pyelonephritis is distinguished by systemic signs: fever, chills, nausea, vomiting, and costovertebral angle (CVA) tenderness.
• Geriatric Presentations: Older adults often present atypically with acute mental status changes (delirium), lethargy, anorexia, or recent falls, frequently in the absence of dysuria, frequency, or fever.
• Diagnostic Testing: Urinalysis typically reveals leukocyte esterase (indicating pyuria) and nitrites (specific for gram-negative enterobacteriaceae like E. coli that reduce nitrates to nitrites). A clean-catch urine culture is the gold standard, defined as >=10^5 colony-forming units (CFU)/mL in females, or >=10^3 CFU/mL in symptomatic females.
• Asymptomatic Bacteriuria: Defined as a positive urine culture in the absence of local urinary symptoms. The FNP must NOT screen or treat asymptomatic bacteriuria in non-pregnant women, older adults, or catheterized patients. Treatment is mandatory only in pregnant women (to prevent pyelonephritis and preterm labor) and patients undergoing invasive urological procedures.
• Pharmacological Management:
  • Uncomplicated Cystitis: First-line options include Nitrofurantoin 100 mg orally twice daily for 5 days, or Trimethoprim-Sulfamethoxazole Double Strength (TMP-SMX DS) 160/800 mg twice daily for 3 days (if local E. coli resistance is <20%), or Fosfomycin 3 g orally in a single dose.
  • Pyelonephritis (Outpatient): Ciprofloxacin 500 mg twice daily for 7 days or Levofloxacin 750 mg daily for 5 days is recommended, provided local fluoroquinolone resistance is under 10%.
  • Pregnancy: First-line options include Cephalexin (Keflex) or Amoxicillin-clavulanate. Nitrofurantoin can be used but must be avoided in the first trimester (risk of congenital anomalies) and at term (38–42 weeks gestation) due to the risk of neonatal hemolytic anemia (hyperbilirubinemia). Fluoroquinolones and tetracyclines are contraindicated.

Nephrolithiasis (Kidney Stones)

Nephrolithiasis is the formation of crystalline stones within the urinary tract.

• Pathophysiology: Supersaturation of urine leads to crystal nucleation. Types include calcium oxalate (75–80%), uric acid (associated with acidic urine and gout), struvite (triple phosphate, associated with urease-producing bacteria like Proteus), and cystine (rare genetic defect).
• Clinical Presentation: Classically presents as sudden onset of severe, colicky, unilateral flank pain that radiates to the lower abdomen, groin, or scrotum/labia. Patients are typically in constant motion, unable to find a comfortable position. Hematuria (gross or microscopic), dysuria, frequency, nausea, vomiting, and diaphoresis are common.
• Diagnostics: Non-contrast helical CT scan of the abdomen and pelvis is the gold standard (highest sensitivity and specificity). Renal ultrasound is the preferred imaging modality for pregnant patients and pediatric populations to avoid radiation exposure. Urinalysis confirms hematuria. Urine pH can guide etiology (pH <5.5 suggests uric acid stones; pH >7.2 suggests struvite stones).
• Management:
  • Spontaneous Passage: Stones <5 mm have a high likelihood of passing spontaneously. Management includes aggressive oral hydration, oral analgesics (NSAIDs like ketorolac are first-line for pain; opioids for severe pain), and alpha-1 blockers (Tamsulosin 0.4 mg daily) to relax ureteral smooth muscle.
  • Referral/Admission: Urological referral is required for stones >10 mm, intractable pain or vomiting, signs of systemic infection (fever, leukocytosis), acute kidney injury, or a stone in a patient with a solitary kidney.

Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia is a non-malignant enlargement of the prostate transition zone, compressing the prostatic urethra.

• Clinical Presentation: Lower Urinary Tract Symptoms (LUTS) are categorized as obstructive (hesitancy, weak stream, post-void dribbling, straining) and irritative (urgency, frequency, nocturia).
• Physical Examination: Digital Rectal Exam (DRE) reveals a smooth, symmetrical, firm, rubbery, non-tender, and enlarged prostate.

• Pharmacological Management:
  • Alpha-1 Adrenergic Antagonists (e.g., Tamsulosin, Terazosin): First-line for rapid symptom relief. They relax smooth muscle in the prostate and bladder neck. Side effects include orthostatic hypotension, retrograde ejaculation, and intraoperative floppy iris syndrome.
  • 5-Alpha-Reductase Inhibitors (e.g., Finasteride): Indicated for moderate-to-severe symptoms with documented prostatic enlargement. They block the conversion of testosterone to dihydrotestosterone (DHT), physically shrinking the prostate over 3–6 months.
  • PSA Correction: Finasteride reduces serum PSA levels by approximately 50%. The measured PSA level must be doubled in patients taking these medications for screening interpretation.

Chronic Kidney Disease (CKD)

Chronic Kidney Disease is defined as kidney damage or an eGFR <60 mL/min/1.73m2 lasting for >=3 months.

• KDIGO Staging: Staging is based on GFR (G1 to G5) and Albuminuria (A1 to A3).
  • G1: GFR >=90 (Normal)
  • G2: GFR 60–89 (Mildly decreased)
  • G3a: GFR 45–59 (Mild-moderate decrease)
  • G3b: GFR 30–44 (Moderate-severe decrease)
  • G4: GFR 15–29 (Severely decreased)
  • G5: GFR <15 (Kidney failure)
  • A1: UACR <30 mg/g (Normal)
  • A2: UACR 30–300 mg/g (Moderately increased)
  • A3: UACR >300 mg/g (Severely increased)
• Management: Blood pressure control target is <130/80 mmHg. ACE Inhibitors (e.g., lisinopril) or Angiotensin II Receptor Blockers (ARBs, e.g., losartan) are first-line for patients with CKD and albuminuria (UACR >=30 mg/g) to reduce intraglomerular pressure by dilating the efferent arteriole, thereby reducing proteinuria. Serum creatinine and potassium must be checked within 1–2 weeks of initiating or adjusting ACEi/ARBs. A creatinine rise of up to 30% from baseline is acceptable and reflects the hemodynamic changes of efferent vasodilation.

Worked Clinical Scenario

A 72-year-old male presents with a history of increasing urinary frequency, nocturia (waking up 3-4 times per night), and a weak urinary stream over the last 12 months. He denies dysuria, hematuria, or perineal pain. On physical examination, a digital rectal exam (DRE) reveals a smooth, symmetrical, firm, non-tender, enlarged prostate estimated at 45 grams. Urinalysis is negative for infection, and his serum PSA is 3.2 ng/mL (within normal limits for age). The patient is started on Tamsulosin 0.4 mg daily to provide rapid relief of his lower urinary tract symptoms, and is counseled on the potential side effects of orthostatic hypotension and retrograde ejaculation.

Clinical Traps & Pearls

• Trap 1: Treating Asymptomatic Bacteriuria. Except in pregnant patients or patients scheduled for invasive urologic procedures, asymptomatic bacteriuria (defined as a positive urine culture without clinical signs or symptoms of UTI) should not be treated with antibiotics. This is especially critical in geriatric patients, where positive cultures are common and treatment does not improve outcomes but increases antibiotic resistance and risk for Clostridioides difficile infection.
• Trap 2: Forgetting to Double PSA with Finasteride. Finasteride halves the serum PSA concentration. If a clinician fails to double the measured PSA value in a patient who has been taking finasteride for 6 months or more, a dangerously elevated PSA (e.g., a measured 3.0 ng/mL, which is actually 6.0 ng/mL) may be overlooked, delaying the diagnosis of prostate cancer.
• Trap 3: Inappropriate Imaging for Nephrolithiasis. While ultrasound is useful, the gold standard for diagnosing nephrolithiasis in an adult is a non-contrast CT scan of the abdomen/pelvis. Relying solely on ultrasound can miss small ureteral stones. However, for pregnant patients and pediatric populations, ultrasound is the correct first-line choice to prevent radiation exposure.